Tango Therapeutics (Tango Therapeutics) Operating Cash Flow per Share : $-1.26 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics Operating Cash Flow per Share?

Tango Therapeutics's operating cash flow per share for the three months ended in Dec. 2023 was $-0.26. Tango Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.26.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Tango Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

TNGX's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Tango Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Tango Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tango Therapeutics Operating Cash Flow per Share Chart

Tango Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

0.80

-0.96

-1.24

-1.25

Tango Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial									-0.32	-0.40	-0.28	-0.32	-0.26

Competitive Comparison of Tango Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Tango Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tango Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tango Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Tango Therapeutics's Price-to-Operating-Cash-Flow falls into.

Tango Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Tango Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-117.982	/	94.572
	=	-1.25

Tango Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-27.467	/	104.485
	=	-0.26

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.26

Tango Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tango Therapeutics (Tango Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215

Website

https://www.tangotx.com

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies.

Executives

Adam Crystal	officer: See Remarks	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
John B Ketchum	director	TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc	director	201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p.	director	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p.	director	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Mva Investors, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron Weitzman	officer: Chief Medical Officer	TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Marc Rudoltz	officer: Chief Medical Officer	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Douglas Barry	officer: See Remarks	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116